HCPCS Code J1120: Acetazolamide sodium injection billing guide

Key takeaways

HCPCS Code J1120 covers the injection of acetazolamide sodium, up to 500 mg, and CMS maintains it under HCPCS Level II.

Medicare pays J1120 under Part B at average sales price plus 6 percent, and the rate changes every quarter.

Medicaid claims need the 11-digit NDC taken from the vial you used, and a missing NDC is the most common denial trigger.

Practice management software like Pabau flags a J1120 claim with missing NDC or diagnosis data before it is submitted.

HCPCS Code J1120 covers the injection of acetazolamide sodium, up to 500 mg. CMS maintains it under HCPCS Level II, and Medicare pays it through Part B using average sales price pricing.

Three problems cause most J1120 denials: a missing NDC, a diagnosis code that does not support the indication, and the wrong place of service.

This guide covers the reimbursement rate, the NDC crosswalk, ICD-10 pairings, documentation requirements, and the buy-and-bill workflow.

HCPCS Code J1120: Definition and quick-reference details

HCPCS Code J1120 is a Level II code maintained by the Centers for Medicare and Medicaid Services (CMS). It reports the injection of acetazolamide sodium, up to 500 mg.

It sits in the J-code series, which covers drugs given by injection or infusion that patients do not self-administer. Store J1120 in your claims management software alongside the payer coverage rules that apply to it.

Acetazolamide sodium: Drug overview and clinical uses

Acetazolamide sodium is a carbonic anhydrase inhibitor. It blocks the enzyme carbonic anhydrase, which reduces bicarbonate formation and lowers fluid pressure in the eye, brain, and kidneys.

The injectable form is used in acute or inpatient settings where oral dosing is not practical. Practices running IV therapy EMR software meet this drug alongside other infused agents, mainly in ophthalmology and neurology workflows.

The injectable form is approved for the conditions below. Each one has its own ICD-10-CM codes, covered in a dedicated section further down.

• Glaucoma: Reduces intraocular pressure in open-angle and secondary glaucoma, and is used acutely when topical agents are not enough
• Epilepsy and seizure disorders: Adjunctive anticonvulsant, mainly in absence seizures that do not respond to first-line agents
• Altitude sickness: Speeds acclimatization by stimulating respiratory compensation, and is most often prescribed in travel clinics
• Edema: Treats drug-induced and congestive cardiac edema, usually as a short-course injection

Coverage policies vary by indication. Medicare and commercial payers may restrict payment to a defined list of diagnoses, so check the applicable Local Coverage Determination (LCD) before you submit.

J1120 Medicare reimbursement rates

Medicare pays HCPCS Code J1120 under the average sales price (ASP) methodology, per 42 CFR 414.904. CMS updates ASP-based drug pricing quarterly, so the rate in force on the date of service is the one that applies. Current rates sit in the CMS Physician Fee Schedule lookup tool.

Key reimbursement facts for J1120 billing teams:

• Payment in a physician office equals ASP plus 6 percent under the Part B drug payment formula
• Hospital outpatient settings are paid under the Outpatient Prospective Payment System (OPPS), which can produce a different rate
• Locality adjustments apply, so rates differ by geographic payment area
• Confirm the current quarter’s ASP pricing in the CMS ASP Drug Pricing Files before you submit

Place of service and ASC payment status for J1120

The place of service (POS) code on a J1120 claim decides which payment system applies and whether the drug is paid separately. The wrong POS is a frequent denial trigger.

The ASC payment indicator for J1120 can change with each annual OPPS and ASC final rule. Verify the current indicator with CMS before you bill in an ASC. Coders can check code-level ASC status in the AAPC Codify HCPCS lookup.

Buy-and-bill billing for HCPCS Code J1120

J1120 is usually billed under the buy-and-bill model. The practice buys acetazolamide sodium, administers it to the patient, and then bills the payer. Your margin is the difference between what the wholesaler charged you and what Medicare pays, so each step below has a financial consequence.

1. Acquire the drug: Buy acetazolamide sodium injectable from a wholesaler or group purchasing organization. Acquisition cost varies by contract, so never bill from a fixed published price.
2. Administer to the patient: Record the drug name, dose, route, quantity, and date of administration in the clinical record before anything reaches the claim.
3. Submit the J1120 claim: Include the correct POS code, the NDC for the product used, the ICD-10-CM codes supporting medical necessity, and the units administered.
4. Reconcile payment against cost: ASP plus 6 percent is designed to approximate cost plus a modest margin. Compare the two each quarter and flag any shortfall to your billing manager.

Acquisition costs move with wholesaler pricing and purchasing contracts, independently of ASP updates. Build the quarterly comparison into your billing workflow so you catch margin compression early.

J1120 NDC crosswalk

National Drug Code (NDC) reporting is required on Medicaid claims and increasingly requested by commercial payers. A J1120 claim sent to Medicaid without an NDC almost always comes back denied.

Your prescription management software should capture the 11-digit NDC at the point of administration, not at the billing stage.

Key NDC reporting rules for J1120:

• Report the 11-digit NDC in 5-4-2 format on CMS-1500 claims, in Box 24A narrative or as an attachment, depending on payer instructions
• NDCs for acetazolamide sodium injectable vary by manufacturer and package size, so check the vial rather than a generic database entry
• The FDA NDC Directory is the authoritative source for confirming a valid NDC number
• Some commercial payers want the NDC qualifier “N4” in front of the code on electronic 837P claims

Verify the NDC against the vial in front of you, not a formulary default. Manufacturers and package sizes change, and the claim has to match the product that was actually administered.

ICD-10 diagnosis codes that support medical necessity for J1120

Every J1120 claim needs at least one ICD-10-CM diagnosis code that establishes medical necessity. The table below lists the codes most often paired with J1120, grouped by clinical indication. Each one matches an FDA-approved use of acetazolamide sodium injectable.

Payer policies can narrow this list further. Check the LCD or coverage determination for your Medicare Administrative Contractor (MAC) before you submit. The NLM Clinical Table Search API serves HCPCS and ICD data programmatically, which is useful for automated eligibility checks.

Documentation requirements for J1120

Thin clinical documentation is the second most common denial reason for J-code drug claims, after NDC errors. Every J1120 claim needs a record that establishes medical necessity and shows the drug was administered. Digital intake forms tied to the encounter capture that detail at the point of care rather than at billing time.

Medical forms that feed the billing module directly shorten the distance between the note and the claim.

Required documentation elements for a valid J1120 claim:

• Physician order: A written order naming acetazolamide sodium, the dose, the route, and the frequency
• Diagnosis linkage: The ICD-10-CM codes in the encounter note must match the codes on the claim
• Drug name, dose, route, and quantity: Recorded in the administration record, with the amount actually drawn and given
• Date of service: The administration date in the clinical note has to match the claim date exactly
• NDC of the product used: Taken from the vial at the time of administration, never from a formulary default
• Administration notes: A short clinical justification confirming the indication and the response to earlier treatment where relevant

Practices subject to HIPAA audits should note that missing documentation on a drug claim can trigger a wider medical record review. Read our guide to HIPAA compliance for the retention obligations that sit alongside these billing rules.

Related and comparable HCPCS codes

Coders who bill J1120 usually handle other injectable J-codes in the same batch. J1364 and J0600 follow the same NDC, unit, and place-of-service rules, so a template built for one carries over.

Two changes are worth noting if you built this list before 2026. CMS deleted J1940 for furosemide with effect from March 31, 2025, and J1938 now carries generic furosemide on a per-milligram basis. Arbutamine, billed under J0395, was discontinued in the Q1 2026 HCPCS update and is no longer billable.

Adenosine, billed under J0153, is the pharmacologic stress agent still in routine use. Descriptions and status change with every annual HCPCS update, so validate each code before you build a billing template around it.

Common billing errors and how to avoid them

Denials for HCPCS Code J1120 cluster around a small number of recurring errors. Most are preventable with workflow controls and EHR integration that connects the clinical record to the claim before submission.

How claims management software prevents J1120 denials

In most practices the three fields that decide a J1120 claim live in three different places. A nurse writes the vial details on an administration record, the physician codes the encounter, and a biller retypes both into the claim. Every hand-off is a chance for one field to go missing.

Practice management software like Pabau keeps those fields on one patient record. The administration note captures the drug, dose, route, and NDC at the point of care. The diagnosis carries through from the encounter note to the claim without being retyped.

Pre-submission rules then check each J1120 claim for a missing NDC, a POS mismatch, or a diagnosis that does not support the indication. The claim is corrected before it leaves the practice. Your team then spends its time on genuine exceptions, not on chasing vial details a week after the appointment.

Stop chasing J-code denials

Pabau’s claims management tools let you build pre-submission validation rules for J1120 and other drug codes. Each rule flags missing NDC data, place-of-service errors, and weak diagnosis linkage before claims leave the practice.

Book a demo

Conclusion

J1120 pays reliably once the vial details, the diagnosis, and the place of service reach the claim unchanged. Fix that path once and these denials stop being a monthly chore.

The trade-off worth remembering is the quarterly one. ASP moves every three months, while your acquisition cost moves on its own schedule. A code that paid well in January can be underwater by July, so put the reconciliation in the calendar.

Book a demo to see how Pabau captures NDC and diagnosis data at the point of administration. Your team can then validate J-code claims before they leave the practice.

Continue your research

Billing another injectable in the same batch? J0585 sets out the unit reporting and documentation a per-unit drug code needs.

Want a second worked example of NDC capture? J0735 covers the same place-of-service and NDC rules on a different injectable.

Counting units on a dose-range code? J0630 shows how unit counting works when one code covers a range of doses.

Billing a high-cost specialty drug? J1322 walks through the documentation an expensive biologic claim has to carry.

Comparing claim scrubbing tools? Pabau vs Waystar compares how each platform validates claims before they are submitted.

Frequently asked questions